Lambert–Eaton myasthenic syndrome – Diagnosis, pathogenesis and therapy
Lambert–Eaton myasthenic syndrome – Diagnosis, pathogenesis and therapy
复制标题
兰伯特·伊顿肌无力综合征 â 诊断、发病机制和治疗
DOI:
10.1016/j.clinph.2014.06.031
复制
发表时间:
2014
影响因子:
4.7
通讯作者:
Hashemolhosseini
中科院分区:
文献类型:
--
作者:
Hülsbrink;Hashemolhosseini
Lambert–Eaton myasthenic syndrome (LEMS) describes a rare human autoimmune disorder of the neuromuscular junction (NMJ). Clinically, LEMS patients suffer from characteristic muscle weakness that is caused by the presence of antibodies directed against their voltage-gated calcium channels (VGCC). These channels are localized in the presynaptic membrane of their motor nerve terminals. Binding of autoimmune antibodies to the VGCCs leads to reduced neuromuscular transmission. In approximately 50% of the patients, LEMS is reflected by a paraneoplastic manifestation and most commonly associated with a small cell lung carcinoma (SCLC) whose cells also express VGCCs in their plasma membrane. Better understanding of the pathophysiological mechanisms of LEMS has helped with the development of new diagnostic approaches and has led to targeted symptomatic and immunosuppressive therapy. For LEMS patients with an underlying malignancy, tumor therapy is the first choice to date.
登录
查看更多内容
DOI:
--
发表时间:
1999
期刊:
Journal of Neurological Sciences
影响因子:
--
作者:
K. Komai;K. Iwasa;M. Takamori
通讯作者:
M. Takamori
DOI:
--
发表时间:
1995
期刊:
Journal of Neurological Sciences
影响因子:
--
作者:
M. Takamori;Masami Takahashi;Y. Yasukawa;K. Iwasa;Y. Nemoto;A. Suenaga;S. Nagataki;Tatsufumi Nakamura
通讯作者:
Tatsufumi Nakamura
影响因子:
11.2
作者:
C. Prior;B. Lang;D. Wray;J. Newsom
通讯作者:
J. Newsom
影响因子:
--
作者:
S. K. Agarawal;B. R. P. Birch;G. F. Abercrombie
通讯作者:
G. F. Abercrombie
DOI:
10.1196/annals.1405.030
发表时间:
2008-01-01
期刊:
MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE
影响因子:
--
作者:
Titulaer, Maarten J.;Verschuuren, Jan J. G. M.
通讯作者:
Verschuuren, Jan J. G. M.